Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops

Cornea. 2014 Sep;33(9):935-41. doi: 10.1097/ICO.0000000000000213.

Abstract

Purpose: The aim of this study was to evaluate the treatment effect of diquafosol 3% with preservative-free sodium hyaluronate 0.1% eye drops in dry eye syndrome.

Methods: In total, 150 patients with dry eye syndrome were divided randomly into 3 groups. Group 1 (50 patients) was treated 4 times daily with preserved sodium hyaluronate 0.1%, group 2 (50 patients) was treated 4 times daily with diquafosol 3%, and group 3 (50 patients) was treated 4 times daily with diquafosol 3% and preservative-free sodium hyaluronate 0.1% eye drops for 3 months. Ocular surface disease index (OSDI) score, tear film break-up time, Schirmer I test, corneal fluorescein staining, and impression cytology were evaluated.

Results: There were significant improvements in the OSDI score, tear film break-up time, Schirmer I score, fluorescein and Rose Bengal staining, goblet cell density, and impression cytological findings in groups 2 and 3 compared with those for group 1 in patients with dry eye syndrome at 1, 2, and 3 months (P < 0.05). There were statistically significant improvements in the OSDI score (-8.48 ± 0.97, -5.69 ± 0.78; P = 0.02), fluorescein (-1.43 ± 0.21, -1.02 ± 0.18; P = 0.03), and Rose Bengal staining (-1.12 ± 0.26, -0.75 ± 0.12; P = 0.03), goblet cell density (89.65 ± 14.39, 70.36 ± 16.75; P = 0.03), and impression cytological findings (-0.53 ± 0.12, -0.34 ± 0.90; P = 0.01) in group 3 compared with those in group 2 at 3 months.

Conclusions: Treatment with diquafosol 3% with preservative-free sodium hyaluronate 0.1% was more effective than diquafosol 3% monotherapy or treatment with preserved sodium hyaluronate 0.1% in dry eye syndrome. Preservative-free sodium hyaluronate 0.1% eye drops can increase the effect of diquafosol 3% in dry eye syndrome.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Drug Combinations
  • Dry Eye Syndromes / diagnosis
  • Dry Eye Syndromes / drug therapy*
  • Dry Eye Syndromes / metabolism
  • Female
  • Fluorescein
  • Fluorescent Dyes
  • Fluorophotometry
  • Humans
  • Hyaluronic Acid / therapeutic use*
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Polyphosphates / therapeutic use*
  • Preservatives, Pharmaceutical
  • Purinergic P2Y Receptor Agonists / therapeutic use*
  • Rose Bengal
  • Tears / chemistry
  • Uracil Nucleotides / therapeutic use*
  • Viscosupplements / therapeutic use*

Substances

  • Drug Combinations
  • Fluorescent Dyes
  • Ophthalmic Solutions
  • Polyphosphates
  • Preservatives, Pharmaceutical
  • Purinergic P2Y Receptor Agonists
  • Uracil Nucleotides
  • Viscosupplements
  • Rose Bengal
  • diquafosol
  • Hyaluronic Acid
  • Fluorescein